The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
0001630113	METASOLUTIONS, INC.		X Corporation
Name of Issuer			Limited Partnership
BIOTRICITY INC.			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organization			Business Trust
NEVADA			Other (Specify)
Year of Incorporation/Organi	zation		
Over Five Years Ago			
X Within Last Five Years (Specify Year) 2012			
Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name	of Issuer			
BIOTRICITY INC.				
Street A	Address 1	Street Address 2		
75 INTERNATIONAL	BLVD., SUITE 300	Suite 300		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
TORONTO	ONTARIO, CANADA	M9W 6L9	(416) 214-3678	

3. Related Persons

Last Name	First Name	Middle Name		
Al-Siddiq	Waqaas			
Street Address 1	Street Address 2			
75 International Blvd.	Suite 300			
City	State/Province/Country	ZIP/PostalCode		
Toronto	ONTARIO, CANADA	M9W 6L9		

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Commercial Banking Insurance Investing Investment Banking Health Hospita Physici	ians Telecommunications acceuticals Other Technology Travel Airlines & Airports
Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Teath Hospita Physici Physici Pharma X Other I Care Manufact Real Esta	als & Computers ians Telecommunications acceuticals Health Travel Airlines & Airports
Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Hospita Physici Pharma X Other Investment Manufact Real Esta Common	als & Computers ians Telecommunications other Technology Travel Airlines & Airports
Energy Finance Coal Mining Resider Electric Utilities Other F Energy Conservation Estate	te Lodging & Conventions ercial Tourism & Travel Services Other Travel Other
Oil & Gas	
Estate	

5. Issuer Size

	Revenue Range	OR	A	ggregate Net Asset Value Range
X	No Revenues			No Aggregate Net Asset Value
	\$1 - \$1,000,000			\$1 - \$5,000,000
	\$1,000,001 - \$5,000,000			\$5,000,001 - \$25,000,000
	\$5,000,001 - \$25,000,000			\$25,000,001 - \$50,000,000
	\$25,000,001 - \$100,000,000			\$50,000,001 - \$100,000,000
	Over \$100,000,000			Over \$100,000,000
	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1) Section 3(c)(9)
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2) Section 3(c)(10)
Rule 504 (b)(1)(iii)	Section 3(c)(3) Section 3(c)(11)
Rule 505	Section 3(c)(4) Section 3(c)(12)
X Rule 506(b)	Section 3(c)(5) Section 3(c)(13)
Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c)(6) Section 3(c)(14)
securities Act Section 4(a)(3)	Section 3(c)(7)

7. Type of Filing

X	New Notice	Date of First Sale	2016-03-31		First Sale Yet to Occur
	Amendment				

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?	Yes X No
--	----------

9. Type(s) of Securities Offered (select all that apply)

	Equity	Pooled Investment Fund Interests
X	Debt	Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination	Yes X No
transaction, such as a merger, acquisition or exchange offer?	1032110

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient		Recipient CRD Number X None	
II (Associated) Broker of Dealer X None		(Associated) Broker or Dealer CRD X None	
Street Address 1		Street Address 2	
City		State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	All States	Foreign/non-US	

13. Offering and Sales Amounts

Total Offering Amount	\$1,000,000	USD	or	Indefinite
Total Amount Sold	\$525,000	USD		
Total Remaining to be Sold	\$475,000	USD	or	Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	4

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0	USD	Estimate
Finders' Fees	\$0	USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD	Estimate
---------	----------

Clarification of Response (if Necessary):

Proceeds will be used for general corporate purposes and working capital, which may include compensation to executive officer in ordinary course.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not

disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
BIOTRICITY INC.	/s/ Waqaas Al-Siddiq	Waqaas Al-Siddiq	Chairman/CEO	2016-04-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their antifraud authority.